United Therapeutics (UTH) Stock Price & Analysis
UTH Stock Chart & Stats
- Day’s Range
- EUR 525.20 - EUR 537.60
- 52-Week Range
- EUR 377.40 - EUR 537.60
- Previous Close
- EUR 535.20
- Volume
- 0
- Average Volume (3M)
- 10
- Market Cap
- EUR 22.92B
- Enterprise Value
- EUR 22.15B
- Total Cash (Recent Filing)
- EUR 2.66B
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- 19.8
- Beta
- 0.26
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- 5.36
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
High Profitability And Cash Generation
United Therapeutics combines unusually high profitability with substantial cash generation, giving it capacity to fund clinical development, commercial expansion and organ-manufacturing initiatives internally. Strong cash conversion also improves resilience and supports flexible capital allocation over the next several quarters.
Conservative Balance Sheet
An essentially debt-free balance sheet gives United Therapeutics significant financial flexibility while reducing interest and refinancing pressure. That position can support investment in pipeline programs, facilities and strategic opportunities without requiring heavy reliance on external financing during periods of business volatility.
Broadening Clinical And Organ Pipeline
Multiple positive clinical readouts and regulatory filings create potential avenues for expanding beyond the existing PAH franchise. Ralinepag, Tyvaso in IPF, additional inhalation devices and xenotransplantation programs could diversify future growth and enlarge the company’s addressable markets.
Bears Say
Sharp Recent Revenue Decline
The sharp TTM revenue decline indicates that recent commercial performance has been uneven despite strong historical profitability. If this volatility persists, it could reduce operating leverage, make investment planning more difficult and delay the conversion of pipeline progress into sustained company-wide growth.
Tyvaso Faces Growing Competition
Competitive pressure on Tyvaso matters because the product generated approximately 58% of Q2 revenue, making the franchise central to near-term results. Greater competition could constrain volume growth, market share and commercial leverage even if patient starts and referrals continue increasing.
Revenue And Regulatory Timing Uncertainty
With 2026 guidance not reaffirmed and approval timing unresolved, the timing of revenue growth remains difficult to forecast. Delays in regulatory decisions or launch execution could postpone contributions from new indications and leave near-term results more dependent on the pressured existing franchise.
United Therapeutics News
UTH FAQ
What was United Therapeutics’s price range in the past 12 months?
What is United Therapeutics’s market cap?
When is United Therapeutics’s upcoming earnings report date?
How were United Therapeutics’s earnings last quarter?
Is United Therapeutics overvalued?
Does United Therapeutics pay dividends?
What is United Therapeutics’s EPS estimate?
How many shares outstanding does United Therapeutics have?
What happened to United Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of United Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
United Therapeutics Stock Smart Score
Company Description
United Therapeutics
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt
- Employees
- 1,400
- Website
- www.unither.com
- Address
- 1040 Spring Street, Silver Spring, MD, 20910, US
United Therapeutics (UTH) Earnings & Revenues
UTH Company Deck
UTH Earnings Call
Earnings Call SentimentPositive
The call balanced significant near-term commercial challenges with very strong clinical and pipeline momentum. Short-term results (Q2 revenue) came in below expectations and Tyvaso faces competitive pressure, creating uncertainty for 2026 revenue. Offsetting this are multiple highly positive Phase III outcomes, major regulatory filings (ralinepag NDA and Tyvaso IPF sNDA), planned additional filings (DPI and SMI), near-complete enrollment for a large PPF trial, aggressive commercial investments (≈100% sales force expansion), and progress across a differentiated xenotransplantation/organ pipeline. Given the material potential of the recent clinical wins and the company’s execution initiatives that could drive meaningful upside in 2027 and beyond, the positives outweigh the near-term lowlights.
View all DE:UTH earnings summariesUTH Net sales Breakdown
- 53.01% Tyvaso
- 21.26% Remodulin
- 15.44% Orenitram
- 8.55% Unituxin
- 1.75% Other
UTH Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 5 |
| Technical Analysis | 3 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |